Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018

Jan 31, 2019
Early recombinant zoster vaccine safety monitoring findings are consistent with prelicensure clinical trial data. Serious adverse events were rare, and no unexpected patterns were detected.

Other news

Cookies help us deliver our services. By using our services, you agree to our use of cookies. What are cookies?